MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Entrada Therapeutics, Inc. - Common Stock (NQ:TRDA)

6.920 +0.340 (+5.17%)
Streaming Delayed Price Updated: 1:28 PM EDT, Jun 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 99,673
Open 6.680
Bid (Size) 6.910 (100)
Ask (Size) 6.930 (200)
Prev. Close 6.580
Today's Range 6.570 - 7.080
52wk Range 4.930 - 16.45
Shares Outstanding 33,197,018
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
From Pomerantz LLP
Via GlobeNewswire
News headline image
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
From Entrada Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-31.1%
-31.1%
1 Month
-56.2%
-56.2%
3 Month
-44.6%
-44.6%
6 Month
-31.3%
-31.3%
1 Year
-16.0%
-16.0%

More News

Read More
News headline image
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
From Pomerantz LLP
Via GlobeNewswire
Entrada Therapeutics (NASDAQ:TRDA) Plunges Nearly 48% as Early-Stage DMD Clinical Data Disappoints on Drug Exposure ↗
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
From Pomerantz LLP
Via GlobeNewswire
News headline image
TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile ↗
Via MarketBeat
Which stocks are experiencing notable movement on Thursday? ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
Which stocks are moving before the opening bell on Thursday? ↗
Via Chartmill
News headline image
Entrada Therapeutics Reports First Quarter 2026 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗
Via The Motley Fool
News headline image
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit ↗
Via The Motley Fool
News headline image
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics to Present at Upcoming Investor Conferences
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company ↗
Via The Motley Fool
Topics Regulatory Compliance

Frequently Asked Questions

Is Entrada Therapeutics, Inc. - Common Stock publicly traded?
Yes, Entrada Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Entrada Therapeutics, Inc. - Common Stock trade on?
Entrada Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Entrada Therapeutics, Inc. - Common Stock?
The ticker symbol for Entrada Therapeutics, Inc. - Common Stock is TRDA on the Nasdaq Stock Market
What is the current price of Entrada Therapeutics, Inc. - Common Stock?
The current price of Entrada Therapeutics, Inc. - Common Stock is 6.920
When was Entrada Therapeutics, Inc. - Common Stock last traded?
The last trade of Entrada Therapeutics, Inc. - Common Stock was at 06/04/26 01:28 PM ET
What is the market capitalization of Entrada Therapeutics, Inc. - Common Stock?
The market capitalization of Entrada Therapeutics, Inc. - Common Stock is 229.72M
How many shares of Entrada Therapeutics, Inc. - Common Stock are outstanding?
Entrada Therapeutics, Inc. - Common Stock has 230M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story